Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high32.00 22/03/17
52 week low6.98 05/09/17
52 week change -7.75 (-39.74%)
4 week volume1,984,921 25/09/17

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
08/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Interim results for six months ended 30 June 2017

RNS Number: 8967R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2017 Southampton, UK - 27 September 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 J...

Data update and clinical plan for COPD

RNS Number: 8968R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD - Significant positive findings in patients with a confirmed viral infection in the INEXAS trial - COPD Phase II clinical trial designed Southampton, UK - 27 Sep...

Holding(s) in Company

RNS Number: 6531Q Synairgen plc 13 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Synairgen Plc 1b. Pleas...

Synairgen's PXS-5382A to be prepared for Phase I clinical development

Synairgen announced following the successful completion of preclinical pharmacology and toxicology studies, a compound...

LOXL2 Inhibitor Update.

RNS Number: 9400P Synairgen plc 06 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') LOXL2 Inhibitor Update - Successful completion of LOXL2 preclinical studies - Phase I trial on track to commence in Q4 2017 Southampton, UK - 6 September 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is please...

Synairgen shareholders pass all resolutions at AGM

Synairgen has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:01pm: (LO...

Result of AGM

RNS Number: 4493J Synairgen plc 28 June 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Result of Annual General Meeting Southampton, UK - 28 June 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting, held earlier today, were duly...

Posting of Annual Report and Notice of AGM

RNS Number: 0559H Synairgen plc 05 June 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Notice of AGM Southampton, UK - 5 June 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, announces that on 2 June 201 7 it posted its full Audited Report and Accounts for the twelve month...

Fundamental DataMore

EPS-3.08
Dividend yield0 %

Latest discussion posts More

  • Pharmaxis on LOXL

    Synairgen partnering Pharmaxis 50/50 as the drug goes into phase 1 trials https://www.youtube.com/watch?v=6uIXJ22ESb4 SNG still hugely undervalued ,....
    8-Sep-2017
    mr1christian
  • Shame.

    Synairgen plc ('Synairgen' or the 'Company') AZD9412 Update ? Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, ...
    27-Apr-2017
    Disorder
  • Re: :-)

    Yes very encouraging. Also waiting for the akzo decision or not? Thanks for the tippage. Up a great deal again!
    10-Mar-2017
    high blood pressure1

Users' HoldingsMore

Users who hold Synairgen also hold..
PREMIER OIL29%
ID:ISIN:VGG9828A119419%
JUBILEE PLAT.19%
ROCKHOPPER16%
AVANTI COMM.16%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG